These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 28702223)

  • 1. The potential role of incretin therapy in the hospital setting.
    Macdonald JJ; Neupane S; Gianchandani RY
    Clin Diabetes Endocrinol; 2015; 1():4. PubMed ID: 28702223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of incretin-based therapy in hospitalized patients with hyperglycemia.
    Umpierrez GE; Schwartz S
    Endocr Pract; 2014 Sep; 20(9):933-44. PubMed ID: 25100362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
    Russell S
    Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical implementation of incretin-based therapy in hospitalized patients with type 2 diabetes.
    Schwartz SS; DeFronzo RA; Umpierrez GE
    Postgrad Med; 2015 Mar; 127(2):251-7. PubMed ID: 25547241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Nauck M
    Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives.
    Seino Y; Kuwata H; Yabe D
    J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):102-9. PubMed ID: 27186364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
    Garber AJ
    Am J Manag Care; 2010 Aug; 16(7 Suppl):S187-94. PubMed ID: 20809667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis.
    Howse PM; Chibrikova LN; Twells LK; Barrett BJ; Gamble JM
    Am J Kidney Dis; 2016 Nov; 68(5):733-742. PubMed ID: 27528374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Debate on Insulin vs Non-insulin Use in the Hospital Setting-Is It Time to Revise the Guidelines for the Management of Inpatient Diabetes?
    Pasquel FJ; Fayfman M; Umpierrez GE
    Curr Diab Rep; 2019 Jul; 19(9):65. PubMed ID: 31353426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of incretin based therapies: clinical trial data.
    White J
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S30-40. PubMed ID: 19801363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretin-based therapies.
    Neumiller JJ
    Med Clin North Am; 2015 Jan; 99(1):107-29. PubMed ID: 25456646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
    Campbell RK
    Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know.
    Waldrop G; Zhong J; Peters M; Rajagopalan S
    J Am Coll Cardiol; 2016 Mar; 67(12):1488-1496. PubMed ID: 27012410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination pharmacotherapy with incretins: what works best and when?
    Over RK; Ratner RE
    Curr Diab Rep; 2008 Oct; 8(5):361-7. PubMed ID: 18778584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretins: their physiology and application in the treatment of diabetes mellitus.
    Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
    Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice.
    Umpierrez GE; Meneghini L
    Endocr Pract; 2013; 19(4):718-28. PubMed ID: 23512382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
    Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
    Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.